DnaK Therapeutics and GATC Health evaluate 16 cancer drug candidates with AI
AI Summary- DnaK Therapeutics and GATC Health will evaluate 16 potential cancer drug candidates.
- 16 candidates will undergo safety, efficacy and off-target-effect analysis using GATC’s Derisq reports.
- Initial results are expected this fall as DnaK works toward selecting a lead candidate.